Asia-Pacific Generic Drugs Market Size, Share and Forecast 2020-2026
Asia-Pacific generic drugs market is estimated to grow at a CAGR of nearly 8.0% during the forecast period. A significant rise in the prevalence of chronic diseases is the major factor accelerating the demand for generic medicines in the region. As per the estimation by the World Health Organization (WHO), the number of new cancer incidences expected to be reported in china was nearly 4.6 million in 2020. Further, the National Cancer Registry Programme estimates that there will be 13.9 lakh new cancer incidences reported in India in 2020, which is expected to rise to 15.7 lakh by 2025.
To Request a Sample of our Report on Asia-Pacific Generic Drugs Market: https://www.omrglobal.com/request-sample/asia-pacific-generic-drugs-market
This, in turn, is leading to
increasing demand for generic drugs in these countries. Cost is the major
benefit associated with the use of generic drugs. The cost of generic drugs can
be up to 85% lower compared to the brand-name drug. Generic drug firms do not
have to invest in high initial drug development costs which results in the low
cost of these drugs compared to branded drugs. The low cost of generics is
acting as a major factor accelerating market growth.
Scope of the Asia-Pacific
Generic Drugs Market
Market Coverage
·
Market number available for 2019-2026
·
Base year- 2019
·
Forecast period- 2020-2026
·
Segment Covered- By Application and Route of
Administration
·
Regions Covered- China, India, Japan, and Rest
of Asia-Pacific
·
Competitive Landscape- Mylan N.V., Teva
Pharmaceutical Industries Ltd., Lupin Ltd., Aurobindo Pharma Ltd., and Sun
Pharmaceutical Industries Ltd.
Recent Strategic
Initiatives in the Asia-Pacific Generic Drugs Market
·
In July 2020, Cipla declared the launch of its
generic version of antiviral drug remdesivir, Cipremi, at $53.3 per 100 mg
vial. This makes it among the lowest cost versions for COVID-19 treatment and
Cipla is looking to deliver more than 80,000 vials within the first month.
·
In July 2020, Mylan launched a generic version
of Remdesivir drug, Desrem, in India for treatment of COVID-19 patients. This
drug will be available at a price of nearly $64.2 per 100 mg vial as against
Hetero’s Covifor at nearly 72.2 per 100 mg vial and Cipla’s Cipremi costing
nearly $53.3 per 100 mg vial.
A full Report of Asia-Pacific
Generic Drugs Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-generic-drugs-market
By Application
·
Cancer
·
CVD
·
Musculoskeletal Diseases
·
Infectious Diseases
·
Neurology
·
Diabetes
·
Others
By Route of
Administration
·
Oral
·
Topical
·
Injectable
·
Inhaler
Asia-Pacific
Generic Drugs Market– Segment by Country
·
China
·
Japan
·
India
Rest of
Asia-Pacific
Company Profiles
·
Abbott Laboratories
·
Aurobindo Pharma Ltd.
·
Cipla Ltd.
·
Dr. Reddy's Laboratories Ltd.
·
Eli Lilly and Co.
·
GlaxoSmithKline plc
·
Glenmark Pharmaceuticals Ltd.
·
Lupin Ltd.
·
Merck & Co., Inc.
·
Mylan N.V.
·
Novartis International AG
·
Novo Nordisk A/S
·
Sun Pharmaceutical Industries Ltd.
·
Teva Pharmaceutical Industries Ltd.
Reasons
to buy from us –
1.
We cover more than 15 major industries, further segmented into more than 90
sectors.
2.
More than 120 countries are for analysis.
3.
Over 100+ paid data sources mined for investigation.
4.
Our expert research analysts answer all your questions before and after
purchasing your report.
For
More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-generic-drugs-market
About Orion
Market Research
Orion Market Research (OMR) is a market research and consulting
company known for its crisp and concise reports. The company is equipped with
an experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment